PanOptica raises $45 million for development of wet AMD eye drop

PanOptica has raised $45 million in series B financing to fund the clinical program for a small-molecule selective inhibitor of VEGF signaling, according to a press release. The compound, PAN-90806, is being investigated as an eye drop treatment for neovascular age-related macular degeneration.

Full Story →